Equities Analysts Issue Forecasts for DNTH FY2025 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Dianthus Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings per share of ($3.46) for the year. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million.

Several other research firms have also recently weighed in on DNTH. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Oppenheimer boosted their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

DNTH opened at $22.66 on Wednesday. The company’s 50-day simple moving average is $23.27 and its two-hundred day simple moving average is $26.31. The stock has a market capitalization of $670.74 million, a P/E ratio of -9.06 and a beta of 1.74. Dianthus Therapeutics has a 52-week low of $14.82 and a 52-week high of $33.77.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after purchasing an additional 814 shares in the last quarter. Quest Partners LLC lifted its stake in shares of Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after buying an additional 1,124 shares in the last quarter. KBC Group NV bought a new position in Dianthus Therapeutics in the 4th quarter worth $35,000. Fred Alger Management LLC increased its stake in Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares in the last quarter. Finally, MetLife Investment Management LLC raised its holdings in Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.